BKHAU
Black Hawk Acquisition Corp
$14.69
0.00%
No data for this timeframe.
Vol
SEC Reports1
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·CIK 0002000775·Prev Close $14.69
Recent Activity
May 8, 2026
SEC
Black Hawk Acquisition Corp., a SPAC, issued a convertible promissory note to its sponsor for up to $300,000 at 10% inte
8-K — Impact 2/10
Mar 19, 2026
Press
Vesicor Therapeutics, the proposed de-SPAC merger target of Black Hawk Acquisition Corp. (BKHAU), has appointed Michael
Impact 4/10
Mar 19, 2026
leadership
Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
<p align="justify">BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc
Latest Reports
NEUTRAL
8-K
2/10
Black Hawk Acquisition Corp., a SPAC, issued a convertible promissory note to its sponsor for up to $300,000 at 10% inte
May 8, 2026
NEUTRAL
Press
4/10
Vesicor Therapeutics, the proposed de-SPAC merger target of Black Hawk Acquisition Corp. (BKHAU), has appointed Michael
Mar 19, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 2.0/10.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Mar 19, 2026
leadership
Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
<p align="justify">BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early developme